One of these compounds, 29 h, has been also shown to restore and potentiate the mitochondrial oxidative stress brought about by venetoclax [136], a Bcl-2-directed drug currently used alone or in combination with anti-CD20 monoclonal antibody for relapsed/refractory in the treatment of CLL [171], to which ROR1-rich CLL cells exhibit low sensitivity [139]. The gene discussed is ROR1; the disease is B-cell chronic lymphocytic leukemia.